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Introduction
• OVCA	is	the	most	deadly	form	of	gynecological	cancers1
• High	rate	of	OVCA	is	correlated	to	the	absence	of	screening	
which	leads	to	diagnosis	of	disease	at	advanced	stages2
• High	fatality	rate	of	OVCA	is	due	to	late	presentation	of	
disease,	cancer	persistence,	and	chemotherapy	resistance3
• A	key	approach	to	combatting	cancer	is	through	activation	
of	the	apoptosis	pathway4
• Momordica	charantia,	commonly	known	as	the	bitter	melon,	
comes	from	the	family	Cucurbitacae5
• Momordica	charantia is	reported	to	have	anti-oxidant,	anti-
inflammatory,	anti-cancer,	anti-diabetic,	anti-bacterial,	anti-
obesity,	and	immunomodulatory	activities	5
• Previous	studies	have	shown	these	anti-cancer	properties	
on	various	forms	of	cancer4
• Specifically,	BG-4,	a	specific	peptide	found	in	Momordica	
charantiawas	shown	to	inhibit	proliferation	in	colon	cancer	
cells	by	promoting	apoptosis	through	down-regulation	of	
anti-apoptotic	proteins,	up-regulation	of	pro-apoptotic	
proteins,	and	modification	of	cell	cycle	proteins4
Objectives
The	objective	of	this	research	is	to	determine	the	ability	of	BG-4	to	cause	
cytotoxicity	to	ovarian	cancer	cells	(A27801AP	and	COV318)	and	determine	
the	mechanism	involved	by	measuring	proteins	associated	with	apoptosis.	
Specifically,
oEffect	of	BG-4	on	Bcl-2	and	XIAP	(anti-apoptotic	proteins)
oEffect	of	BG-4	on	BAX	and	capsase-3	(pro-apoptotic	proteins)
oEffect	of	BG-4	on	p21	and	CDK2	(cell	cycle	proteins)
Results
Effect of BG-4 on  OVCA cell proliferation 
Figure 1. BG-4 purified from Momordica
chrantia caused dose-dependent
cytotoxicity in COV318 OVCA cells. BG-4treatment led to a decrease in viable cellcount by 19.8% at 250 μg/mL. Mean valuesrepresented as bars with different letter(s)are statistically different from each other(P<0.05, n=2).
Effect of BG-4 on apoptotic markers
Cell cycle markers
Conclusions
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Figure 2. BG-4 purified from Momordica
chrantia caused dose-dependent
cytotoxicity in 1AP (A27801AP) OVCA cells.BG-4 treatment led to a decrease in viable cellcount by 65.1% at 250 μg/mL. Mean valuesrepresented as bars with different letter(s)are statistically different from each other(P<0.05, n=2).
Figure 4. BG-4 modified expressions of cell cycle proteins in 1AP OVCA cell
line). BG-4 increased the expression of p21 (a) leading to a reduction inexpression of CDK2 (b). All analyses were done in at least two independentreplicates. Mean values represented as bars with different letter(s) are statisticallydifferent from each other (P<0.05, n=2)
• BG-4	from	Momordica	charantia possesses	anti-cancer	properties
• BG-4	has	the	capability	of	activating	apoptosis	in	human	ovarian	
cancer	cells
• The	findings	support	the	idea	for	potential	use	of	BG-4	as	an	
ovarian	cancer	therapeutic	agent	and	should	be	further	studied	
using	in	vivo	models	of	ovarian	carcinogenesis
Experimental Design
BG-4 induces apoptosis in OVCA 1AP cells as measured by flow cytommetry.Quantification of OVCA cells undergoing apoptosis as a result of BG-4 treatment. Thelive cells were from 89.955% (untreated) to 73.92% and 68.83% for 125 μg/mL and250 μg/mL treatment, respectively. Early apoptotic cells were from 7.10%(untreated) to 20.99% and 23.95% for 125 μg/mL and 250 μg/mL treatment,respectively. Late apoptotic cells were from 1.965% (untreated) to 3.72% and 5.37%for 125 μg/mL and 250 μg/mL treatment, respectively. Necrotic cells were from0.98% (untreated) to 1.36% and 1.81% for 125 μg/mL and 250 μg/mL treatment,respectively. Mean values represented as bars with different letter(s) are statisticallydifferent from each other (P<0.05, n=2).Figure 3. BG_4 modified expression of apoptotic proteins. (a) BG-4 promotedapoptosis by increasing caspase-3 (a) and BAX (b) leading to a reduced expression of
XIAP (c) and no change in expression of Bcl-2 (d). Mean values represented as bars
with different letter(s) are statistically different from each other (P<0.05, n=2).
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